In the past few years, several transplantations of enzyme-producing cells or tissues have been performed in an attempt to continuously produce active enzymes in patients suffering from .g .-150 1 mucopolysaccharidoses (1,2, 3).
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Reporting the successful results of HLA-compatible fibroblast Both parents had a low enzyme activity in their serum (4.2 and Time (days) 3.9 nmole/h/ml for the mother and the father respectively; control mean * 1 S.D. = 16.7 * 6.7 nmole/h/ml, = 19) but they were Fig. 1 . N-acetyl-a-glucosaminidase activity in serum from Sanfilippo clinically normal and they had no heparane sulfaturia. (5). The donor was HLA-identical to his sister and he displayed no mixed leukocyte reaction against the recipient. Fibroblast culture and transplantation were performed as described (l), and Indeed, the intracellular half-life of N-acetyl-a-glucosaminidase approximately 2 x 10' viable cells were injected as a cell suspension is known to be short (5); infusions of HLA-compatible leukocytes into four subcutaneous dorsal sites, which were located by der-in Sanfilippo B disease only resulted in a transient effect on matological methods.
urinary GAG excretion (4). However, this explanation could not N-acetyl-a-glucosaminidase activity in serum and glycosami-account for our results if one assumes that implanted donor noglycan (GAG) elimination in the urines were followed before fibroblasts can survive and even proliferate in the recipients' and after transplantation. As shown in Figure 1 , no significant subcutaneous space (1). modifications in enzyme activity were noted in serum after grafting Consequently, in spite of the negativity of mixed leukocyte and the excretion of urinary GAG remained unchanged over a reaction after grafting, one has to consider the possibility of a graft period of 4 months. rejection, especially as no immunosuppressive therapy was given. In order to evaluate the implantation of donor fibroblasts in the In our opinion, the decision of an immunosuppressive therapy recipients' tissues, our patient unde~;-ent three full-thickness skin for fibroblast transplantation is questionable. We are reluctant to biopsies at the very same place where cell suspension was injected take such a heavy decision for a therapeutic trial which has little 2 months earlier. The fibroblasts cultured from these biopsies were chance of clinical success if one compares the amount of accutested for enzyme activity. The activity was found to be zero in mulated substances to the small number of transplanted cells. the three independent specimens tested.
However, in contrast to cell transplantation, an immunosuppresIn addition, only female caryotypes were found in the cultured sive therapy could be reasonably decided for an organ transplancells which were examined. tation since the risk of an efficient immunosuppression is counterThese data suggest that in our patient, the implanted fibroblasts balanced by the expectation of a possible clinical improvement. did not survive or proliferate in situ. The failure to produce any measurable effect also precludes the possibility of a significant cell 
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We transplanted HLA compatible fibroblasts into several patients with different types of mucopolysaccharidoses in an attempt to provide a long lasting source of lysosomal enzymes for replacement therapy (Dean et al. 3, 4, 5) .
In one group of patients deficient in a-L-idurono-2-sulphate sulphatase (Hunter syndrome) and another group deficient in glucosamine-N-sulphate sulphatase (Sanfilippo A syndrome), we observed a number of biochemical changes subsequent to a single transplant. These changes included increased excretion of accumulated glycosaminoglycan storage products, a reduction in the relative proportions of higher molecular weight oligosaccharides and a marked reduction in their degree of oversulphation. Coupled with these changes we observed an increase in the activity of previously deficient lysosomal enzymes measured as excreted "corrective factors". All the above effects persisted for many months.
However, we were unable to demonstrate any consistent changes following a similar transplant in a group of two patients with a-L-iduronidase deficiency (Hurler syndrome), Dean et al. unpublished data. Neither were we able to detect a consistent increase in glucosamine-N-sulphatase activity in our patients with Sanfilippo disease when [35S]-labeled heparin was used as a substrate for direct enzyme assay. Leucocytes and serum samples taken from two of our Hunter patients more than a year after transplant did, however, h a v~ slightly higher levels of a-L-idurono-2-sulphate sulphatase than age matched control untreated patients when tested against a ["HI-labeled disulphated disaccharide substrate.
All our patients exhibited severe primary and secondary symptoms of their diseases prior to transplant and we did not detect sustained clinical improvements in any of them following treatment.
The intracellular half lives of most lysosomal enzymes are very short, a-L-idurono-2-sulphate sulphatase and glucosamine-N-sulphatase for example each being only 2 days after uptake into fibroblasts [Cantz et al., (2) , Kresse and Neufeld (7)]. The long lasting effects we observed following single transplants of fibr; blasts could only therefore be explained if at least some of the fibroblasts had survived and continued to secrete lysosomal enzymes. The fact that a relatively small number of transplanted cells induced such large changes in excreted enzymes and GAG led us to speculate that perhaps the transplanted cells may have divided in vivo. We do not however have any direct evidence that either supposition is correct. We ourselves have no experience with Sanfilippo B patients. Since this syndrome results from a glycosidase deficiency rather than absence of a sulphatase, however, it may be less amenable to replacement therapy than sulphatase deficiencies such as Hunter and Sanfilippo A diseases. Furthermore, since each lysosomal enzyme deficiency other than those within the same pedigree is attributable to a separate gene mutation, there may be considerable variation in responsiveness even within a group of patients with the same inborn error. Other discrepancies may result from differences in experimental protocol. Lack of immunosuppression before transplant for example may explain the failure of graft survival. The method employed for enzyme assay is also important. Detection of previously deficient enzymes by correction of [35S]-sulphate incorporation has been shown to be 14 times more sensitive than direct enzyme assay in the case of /?-glucuronidase [Brot et 
